Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary (Japan)

Blogger's Note: important to note that clear cell ovarian cancer is diagnosed at significantly higher rates than other countries and may represent a distinct phenotype

open access:
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

Frequent mutation of the ARID1A gene has been recently identified in ovarian clear‑cell adenocarcinoma (CCA); however, the clinical significance of BAF250a expression encoded by the ARID1A gene remains to be determined. The aim of the present study was to assess whether BAF250a expression had an impact on the clinical features of CCA....Although loss of BAF250a expression was associated with early tumorigenesis in endometriosis‑related CCA, this alteration was not significantly correlated with chemosensitivity and prognoses of CCA. Further biomarker analyses, including BAF250a expression, are required to improve the prognoses of CCA.

 Patients

A total of 97 cases of CCA treated between 1984 and 2007 at the National Defense Medical College Hospital, (Tokorozawa, Japan) were enrolled in the present study. Of the 97 CCAs, a consecutive series of 38 CCAs synchronous with endometriosis (EM-related CCAs) and 21 CCAs adjacent to CCAF component (CCAF-related CCAs) were identified, according to the histopathological criteria described previously (18). Of those, 31 non-atypical endometrioses, 38 atypical endometrioses, 20 benign CCAFs and 21 borderline CCAFs were identified. A total of 18 cases with solitary endometriosis that had no CCA were used as controls.